Add UPTRAVI® Earlier in FC II and FC III Before Progression Takes More Away1
PRIMARY ENDPOINT: TIME TO FIRST PAH DISEASE PROGRESSION EVENT IN GRIPHON1,2
Time to first disease progression event
Time to first disease progression event
The treatment effect was established early and maintained over the entire treatment period
Summary of primary endpoint events
*Hazard ratio based on primary endpoint events up to the end of treatment.
6MWD=6-minute walk distance; CI=confidence interval; FC=Functional Class; GRIPHON=Prostacyclin (PGI2) Receptor Agonist In Pulmonary Arterial HypertensiON; HR=hazard ratio.
References:1. UPTRAVI® (selexipag) full Prescribing Information. Actelion Pharmaceuticals US, Inc. 2. Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373:2522-2533.
This site is intended for U.S. healthcare professionals
Clicking continue below will take you to the selected site, the content for which Janssen is not responsible and to which this Privacy Policy does not apply. We encourage you to read the Privacy Policy of every online service you visit.
After the starting dose of 200 mcg twice daily, all patients completed titration to their maintenance dose within the first 12 weeks, up to a maximum dose of 1600 mcg twice daily.
Primary endpoint: time to first PAH disease progression event
Death
Hospitalization for PAH
Need for lung transplantation or balloon atrial septostomy for worsening of PAH
Parenteral prostanoid or chronic oxygen therapy
Other disease progression (decrease in 6MWD plus worsening of FC or need for other therapy)
Baseline patient characteristics
Mean age: 48 years
Female: 80%
*Other=drugs and toxins (2%) and HIV (1%).
6MWD=6-minute walk distance; ERA=endothelin receptor antagonist; FC=Functional Class; GRIPHON=Prostacyclin (PGI2) Receptor Agonist In Pulmonary Arterial HypertensiON; HIV=human immunodeficiency virus; HPAH=heritable PAH; IPAH=idiopathic PAH; PAH-CHD=PAH associated with congenital heart disease with repaired shunts; PAH-CTD=PAH associated with connective tissue disease; PDE-5i=phosphodiesterase type-5 inhibitor; WHO=World Health Organization.
References: 1. UPTRAVI® (selexipag) full Prescribing Information. Actelion Pharmaceuticals US, Inc. 2. Ruopp NF, Cockrill BA. Diagnosis and treatment of pulmonary arterial hypertension: a review. JAMA. 2022;327(14):1379-1391. 3. Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373:2522-2533. 4. Coghlan JG, Channick R, Chin K, et al. Targeting the prostacyclin pathway with selexipag in patients with pulmonary arterial hypertension receiving double combination therapy: insights from the randomized controlled GRIPHON study. Am J Cardiovasc Drugs. 2018;18(1):37-47.
UPTRAVI® WAS STUDIED IN GRIPHON, A LARGE OUTCOMES TRIAL IN PAH (N=1156)1
After the starting dose of 200 mcg twice daily, all patients completed titration to their maintenance dose within the first 12 weeks, up to a maximum dose of 1600 mcg twice daily.
Primary endpoint: time to first PAH disease progression event
Death
Hospitalization for PAH
Need for lung transplantation or balloon atrial septostomy for worsening of PAH
Parenteral prostanoid or chronic oxygen therapy
Other disease progression (decrease in 6MWD plus worsening of FC or need for other therapy)
Baseline patient characteristics
Mean age: 48 years
Female: 80%
*Other=drugs and toxins (2%) and HIV (1%).
6MWD=6-minute walk distance; ERA=endothelin receptor antagonist; FC=Functional Class; GRIPHON=Prostacyclin (PGI2) Receptor Agonist In Pulmonary Arterial HypertensiON; HIV=human immunodeficiency virus; HPAH=heritable PAH; IPAH=idiopathic PAH; PAH-CHD=PAH associated with congenital heart disease with repaired shunts; PAH-CTD=PAH associated with connective tissue disease; PDE-5i=phosphodiesterase type-5 inhibitor; WHO=World Health Organization.
Reference: 1. UPTRAVI® (selexipag) full Prescribing Information. Actelion Pharmaceuticals US, Inc.
